Skip to main content

Incyte Reports Decreased Q3 Revenues, Widened Losses

NEW YORK, Nov. 4 (GenomeWeb News) - Incyte today reported significantly decreased third-quarter revenues, and widened net losses.


The Palo Alto, Calif., company reported revenues of $13.2 million for the third quarter, compared to $22.4 million for the same period last year. Net loss widened to $43.0 million, from $38.4 million for the third quarter of 2002.


R&D expenses were down to $28.6 million, from $47.4 million in the third quarter of 2002.


As of Sept. 30, Incyte had $315.1 million in cash and cash equivalents.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.